News and Announcements
Carl Zeiss Meditec AG Product Orders
- Published January 10, 2021 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Highlights:
• Receipt of orders from Carl Zeiss Meditec AG (CZM) for approx. A$350k
• Continued diversification of OptiScan Revenue Streams with receipts of A$570k from the balance of the payments for the 2 FIVE2 (ViewnVivo) sales to China based customers, the BioMedTech Horizons Program grant and from CZM in the December 2020 quarter.
Carl Zeiss Meditec AG Orders
OptiScan Imaging Limited (ASX: OIL) (‘the Company’ or ‘OptiScan’) is pleased to advise that it has received orders from Carl Zeiss Meditec AG pursuant to its Co-operation Agreement for approximately A$350k.
OptiScan’s CEO and Executive Chairman Darren Lurie, said:
“The orders from CZM represent the continuation of CZM’s commercial rollout of the CONVIVO® developed as part of the co-operation agreement between CZM and OptiScan.
We are also very pleased that OptiScan continues to diversify its revenue streams and cash flows. Receipts in the December 2020 quarter included $570k from the final payments for the 2 (two) FIVE2 (ViewnVivo) systems sold to China based customers, the BioMedTech Horizons Program grant to support the University of Melbourne’s Melbourne Dental School trial and payments from CZM. ”
About Optiscan Imaging Limited (ASX:OIL)
OptiScan (ASX:OIL) is an Australian listed company and a pioneer in the development and application of endomicroscopic imaging technologies for medical markets. Our multi-patented confocal imaging technology can be used for both cancer screening and tumour margin detection in cancer surgery. Our device enables real-time, in vivo imaging at the cellular level in clinical applications, providing a “digital” biopsy. The benefits of this “digital” biopsy include monitoring of early stage disease, earlier identification of pre-cancer and the potential to reduce the time doctors, patients and operating theatres are required to wait for pathology results, the number of repeat surgeries and actual biopsies required.
Optiscan has a collaboration with leading European medical technology company, Carl Zeiss Meditec AG and our technology is a critical part of the ZEISS CONVIVO™, that has brought OptiScan’s technology into the field of Neurosurgery. FDA 510(k) clearance and CE Mark have been obtained for the ZEISS CONVIVO™.
Company Updates
Tony Seba’s “Stellar Abundance” – A Roadmap for Strategic Investment in the Next Exponential Growth Era
In a recent conversation with Herbert Ong on the “Brighter with Herbert” YouTube channel, visionary author and co-founder of RethinkX and Stellar, Tony Seba, outlines a profoundly ambitious and positive outlook on the future, making recent market analyses of substantial changes seem comparatively minor. While the focus often remains on the growing opportunities within specific […]
Fundraising Realities and Strategic Engagement Imperative
Sydney-based CapitalHQ, a platform founded by Steve Torso of Wholesale Investor, has reached its first anniversary, a milestone marked by a notable shift in its operational model. Torso, in a recent address, not only celebrated this juncture but also provided a grounded assessment of the prevailing challenges in capital raising, advocating for a more strategic […]
Hong Kong: Your Strategic Launchpad into Asia’s High-Growth Markets
Explore the unique benefits Hong Kong offers as a strategic launchpad for companies looking to access the high-growth markets of Mainland China and Southeast Asia, leveraging its favorable business environment and international connections.
Backed By Leading Investment Groups and Family Offices
